Discussing Lebrikizumab Treatment Adherence and Flexibility Long-Term

In Part 2 of this HCPLive Special Report series, Raj Chovatiya, MD, PhD—clinical associate professor at Rosalind Franklin University Chicago Medical School and director of the Center for Medical Dermatology and Immunology Research—discusses the long-term dosing flexibility of lebrikizumab in recent findings highlighting moderate-to-severe atopic dermatitis.1

Chovatiya interprets new data showing comparable efficacy between biweekly (Q2W) and monthly (Q4W) maintenance dosing as a meaningful step forward in personalized atopic dermatitis care. For patients who respond well during the induction phase, he notes that Q4W dosing can still maintain—or in some cases, enhance—clinical response over time. This durability, he says, offers an opportunity to simplify treatment regimens without compromising outcomes.

He acknowledges that many clinicians default to more frequent dosing but sees value in the product label’s structure, which begins with Q2W dosing for four months before transitioning to a more individualized plan. Chovatiya encourages dermatologists to use this transition point to engage in shared decision-making with patients based on their response, goals, and preferences.

Framing lebrikizumab as a long-term, disease-modifying therapy, Chovatiya stresses the importance of setting realistic expectations and emphasizing sustained care to achieve optimal disease control, including skin clearance, itch reduction, and stability over time.

Editor's note: This summary was created with the help of artificial intelligence tools.

References

1. Chovatiya R, et al. Raising the Bar of Efficacy in Atopic Dermatitis: Lebrikizumab Maintains Depth of Response Over 3 Years in Week 16 Responders. Presented at: 2025 Revolutionizing Atopic Dermatitis (RAD) Conference; June 6-7, 2025; Nashville, TN.

2. FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis. September 13, 2024. Accessed June 18, 2025. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-ebglysstm-lebrikizumab-lbkz-adults-and.